Evidence map›Paper›PMID 31194009›Full record

ArticleMolecular therapy. Methods & clinical development2019

Endothelin-1 Augments Therapeutic Potency of Human Mesenchymal Stem Cells via CDH2 and VEGF Signaling.

Eun Ju Lee, Injoo Hwang, Gi-Hwan Kim, Dodam Moon, Su Yeon Kang, In-Chang Hwang, Seo-Yeon Lee, P J Marie, Hyo-Soo Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Eun Ju LeeBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Injoo HwangMolecular Medicine & Biopharmaceutical Sciences, Seoul National University, Seoul 03080, Republic of Korea.
Gi-Hwan KimMolecular Medicine & Biopharmaceutical Sciences, Seoul National University, Seoul 03080, Republic of Korea.
Dodam MoonMolecular Medicine & Biopharmaceutical Sciences, Seoul National University, Seoul 03080, Republic of Korea.
Su Yeon KangBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
In-Chang HwangDivision of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Seo-Yeon LeeBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
P J MarieUMR-1132 INSERM and University Paris Diderot, Sorbonne Paris Cité, Hôpital Lariboisiére, Paris, France.
Hyo-Soo KimMolecular Medicine & Biopharmaceutical Sciences, Seoul National University, Seoul 03080, Republic of Korea.
Seoul National University · KRSeoul National University Hospital · KRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In our previous study, we identified differences in the levels of CDH2 and vascular endothelial growth factor (VEGF) between effective and ineffective clones of human umbilical cord blood (hUCB) mesenchymal stem cells (MSCs), with regard to the infarcted rat myocardium. In this study, we compared gene expression profiles between the effective and ineffective clones and identified that endothelin-1 (

Indexed as

endothelin-1human umbilical cord blood mesenchymal stem celltherapeutic potency

Identifiers

PMID31194009
PMCPMC6545354
OpenAlexW2945586633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.